Xilio therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Waltham, mass., oct. 02, 2024 (globe newswire) -- xilio therapeutics, inc. (nasdaq: xlo), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective october 1, 2024, the compensation committee of the board of directors granted non-qualified stock options to purchase an aggregate of 101,000 shares of its common stock to three new employees under xilio therapeutics' 2022 inducement stock incentive plan.
NDAQ Ratings Summary
NDAQ Quant Ranking